Endocrine Abstracts

Introduction: Obstructive sleep apnea (OSA) affects up to 20% of a Western population and is associated with non-alcoholic fatty liver disease and type 2 diabetes (T2D). OSA is characterized by intermittent episodes of hypoxia (IH) that occur during sleep. It is not yet known if IH is directly linked to insulin resistance within key metabolic target tissues (adipose; liver and skeletal muscle) and what the potential underlying mechanism may be. It has been suggested that indiv...

Background: Clinical experience has shown that men over 60 years of age frequently (40%) require extended intervals of greater than 12 weeks between administrations of Nebido. No work has assessed whether this is specific to men over 60 years of age.Methods: We analysed men on Nebido over 60 years (n=12, mean age 66 years) and compared them with a BMI matched group aged 40–60 years. We assessed testosterone levels, injection intervals, PSA an...

Aim: In normal men testosterone levels fall with age. We wished to assess the efficacy and safety of Nebido in men over the age of 60 years in order to assess dose frequency and other potential complications.Subjects and methods: Ten men over 60 years of age (range 60–77 median 64) with primary or secondary hypogonadism were treated with Nebido 1000 mg i.m. Each was given a loading dose of two injections 6 weeks apart (our normal protocol for all pa...

Glucocorticoid (GC) excess drives obesity, insulin resistance and type 2 diabetes. Obstructive sleep apnoea (OSA) is a prevalent condition associated with both activation of the hypothalamic-pituitary-adrenal (HPA) axis and an adverse metabolic phenotype. However, a causal link between these two features has not been established. We designed a novel human model of intermittent hypoxia (IH) aimed at replicating the systemic insulin resistance associ...

Glucocorticoid (GC) excess drives obesity, insulin resistance and type 2 diabetes. Obstructive sleep apnoea (OSA) is a prevalent condition associated with both activation of the hypothalamic-pituitary-adrenal (HPA) axis and an adverse metabolic phenotype. However, a causal link between these two features has not been established. We designed a novel human model of intermittent hypoxia (IH) aimed at replicating the systemic insulin resistance associ...